In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences

Ángel M. Cuesta, David Sánchez-Martín, Laura Sanz et al. · 2009

Read In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences by Ángel M. Cuesta, David Sánchez-Martín, Laura Sanz et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0005381.txt.

Description

Cancer therapy needs agents that find tumors in the body and mark them for imaging or attack. Cuesta and colleagues built such an agent, a trivalent antibody fragment they call a trimerbody, and tested it in living animals in PLOS ONE in 2009.

The trimerbody joins a single-chain antibody fragment to a collagen-derived section that holds three arms together. Three binding arms grip tumor targets more firmly than one. In vivo tests showed the engineered fragments target tumors and support imaging, a step toward clinical scanners. Three arms cost more to make than one, so the gain must be real in the body. Not just in a dish, and the live tests here are the ones that count for that claim.

Catalog record

CREATORÁngel M. Cuesta, David Sánchez-Martín, Laura Sanz et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005381

Browse the full library · About the Tower of Babel